Search - tctmd.com

Displaying 921 - 940 of 1102

Sort: Relevancy | Date

News Industry News

Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year

October 22, 2012

News Daily News

New Class of Oral Anticoagulants Safer Compared with Warfarin for A-fib

October 19, 2012

News Industry News

Revascularization with OrbusNeich’s Genous™ Stent May Enable the Safe and Early Discontinuation of Dual Antiplatelet Therapy for Patients with Increased Bleeding Risk

October 12, 2012

News Daily News

Almost 1 in 10 STEMIs Caused by Stent Thrombosis

October 12, 2012

News Daily News

Drug-eluting Balloons Show Positive Results in Treating In-stent Restenosis

Jason Kahn

October 05, 2012

News Daily News

Meta-analysis Looks at Novel Anticoagulants Plus Dual Therapy in ACS Patients

October 02, 2012

News Daily News

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

September 20, 2012

News Daily News

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

September 20, 2012

Presentation

RESET Trial: A New Strategy for Discontinuation of Dual Antiplatelet Therapy

Presenter: B-K Kim

September 19, 2012

News Daily News

Efficacy of Clopidogrel Diminished in Diabetics After MI

September 07, 2012

News Conference News ESC 2012

Stem Cells, Nanoparticles Appear to be an Antidote to Atherosclerosis

Caitlin E. Cox

August 29, 2012

News Conference News ESC 2012

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

Caitlin E. Cox

August 29, 2012

News Conference News ESC 2012

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Yael L. Maxwell

August 28, 2012

News Conference News ESC 2012

Stent Thrombosis Surprise: Rates Low, Similar for Endeavor and Cypher at 3 Years

August 27, 2012

News Conference News ESC 2012

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

Caitlin E. Cox

August 27, 2012

News Conference News ESC 2012

ESC Congress 2012 Offers Slate of Guidelines, New MI Definition

Caitlin E. Cox

August 26, 2012

News Daily News

COMFORTABLE AMI Published: Biodegradable-Polymer DES Bests BMS in STEMI

Yael L. Maxwell

August 23, 2012

News Daily News

Study Suggests Shortening Delay to Noncardiac Surgery After PCI

Yael L. Maxwell

August 17, 2012

News Daily News

No Safe Window for Triple Antithrombotic Therapy in High-Risk A-fib Patients

August 14, 2012

News Daily News

JAMA Viewpoint: TAVR Promise Must Be Weighed Against Risks, Limitations

Yael L. Maxwell

August 09, 2012

Advertisement

Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year

New Class of Oral Anticoagulants Safer Compared with Warfarin for A-fib

Revascularization with OrbusNeich’s Genous™ Stent May Enable the Safe and Early Discontinuation of Dual Antiplatelet Therapy for Patients with Increased Bleeding Risk

Almost 1 in 10 STEMIs Caused by Stent Thrombosis

Drug-eluting Balloons Show Positive Results in Treating In-stent Restenosis

Meta-analysis Looks at Novel Anticoagulants Plus Dual Therapy in ACS Patients

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

RESET Trial: A New Strategy for Discontinuation of Dual Antiplatelet Therapy

Efficacy of Clopidogrel Diminished in Diabetics After MI

Stem Cells, Nanoparticles Appear to be an Antidote to Atherosclerosis

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Stent Thrombosis Surprise: Rates Low, Similar for Endeavor and Cypher at 3 Years

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

ESC Congress 2012 Offers Slate of Guidelines, New MI Definition

COMFORTABLE AMI Published: Biodegradable-Polymer DES Bests BMS in STEMI

Study Suggests Shortening Delay to Noncardiac Surgery After PCI

No Safe Window for Triple Antithrombotic Therapy in High-Risk A-fib Patients

JAMA Viewpoint: TAVR Promise Must Be Weighed Against Risks, Limitations

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content